Cigarette pack messages about toxic chemicals: A randomised clinical trial

Background The USA can require tobacco companies to disclose information about harmful and potentially harmful chemicals in cigarette smoke, but the impact of these messages is uncertain. We sought to assess the effect of placing messages about toxic chemicals on smokers' cigarette packs. Methods Participants were 719 adult cigarette smokers from California, USA, recruited from September 2016 through March 2017. We randomly assigned smokers to receive either factual messages about chemicals in cigarette smoke and their health harms (intervention) or messages about not littering cigarette butts (control) on the side of their cigarette packs for 3 weeks. The primary trial outcome was intention to quit smoking. Results In intent-to-treat analyses, smokers whose packs had chemical messages did not have higher intentions to quit smoking at the end of the trial than those whose packs had control messages (P=0.56). Compared with control messages, chemical messages led to higher awareness of the chemicals (28% vs 15%, P<0.001) and health harms (60% vs 52%, P=0.02) featured in the messages. In addition, chemical messages led to greater negative affect, thinking about the chemicals in cigarettes and the harms of smoking, conversations about the messages and forgoing a cigarette (all P<0.05). Discussion Chemical messages on cigarette packs did not lead to higher intentions to quit among smokers in our trial. However, chemical messages informed smokers of chemicals in cigarettes and harms of smoking, which directly supports their implementation and would be critical to defending the messages against cigarette company legal challenges. Trial registration number NCT02785484

Public Understanding of Cigarette Smoke Chemicals: Longitudinal Study of US Adults and Adolescents

Introduction: The US Food and Drug Administration has increased communication efforts that aim to raise public awareness of the harmful constituents (ie, chemicals) in cigarette smoke. We sought to investigate whether the public's awareness of these chemicals has increased in light of such efforts. Methods: Participants were national probability samples of 11 322 US adults and adolescents recruited in 2014-2015 (wave 1) and 2016-2017 (wave 2). Cross-sectional telephone surveys assessed awareness of 24 cigarette smoke chemicals at both timepoints. Results: The proportion of US adults aware of cigarette smoke chemicals did not differ between waves 1 and 2 (25% and 26%, p =. 19). In contrast, awareness of chemicals among adolescents fell from 28% to 22% (p <. 001), mostly due to lower awareness of carbon monoxide, arsenic, benzene, and four other chemicals. Belief that most of the harmful chemicals in cigarette smoke come from burning the cigarette also fell from waves 1 to 2 (adults: 31% vs. 26%; adolescents: 47% vs. 41%, both ps <. 05). Participants were more likely to be aware of cigarette smoke chemicals if they had been exposed to anti-smoking campaign advertisements (p <. 05) or had previously sought chemical information (p <. 05). Cigarette smoke chemical awareness did not differ between smokers and nonsmokers. Conclusion: Awareness of cigarette smoke chemicals remains low and unchanged among adults and decreased somewhat among adolescents. The association of chemical awareness with information exposure via campaigns and information seeking behavior is promising. More concerted communication efforts may be needed to increase public awareness of cigarette smoke chemicals, which could potentially discourage smoking. Implications: Awareness of the toxic chemicals in cigarette smoke may contribute to quitting. The US Food and Drug Administration is making efforts to increase public awareness of these chemicals. Two national surveys (2014-2017) found that chemical awareness was low among adults and adolescents. Although awareness did not change among adults, awareness among adolescents dropped over time. In addition, exposure to anti-smoking campaigns and chemical information seeking behavior were associated with higher awareness of chemicals in cigarette smoke. Campaigns and other efforts may be needed to increase awareness of cigarette smoke chemicals

A Maximum Information Rate Quaternion Filter for Spacecraft Attitude Estimation

Building on previous works, this paper introduces a novel continuous-time stochastic optimal linear quaternion estimator under the assumptions of rate gyro measurements and of vector observations of the attitude. A quaternion observation model, which observation matrix is rank degenerate, is reduced to a two-dimensional model via a maximum information rate approach. The resulted filter combines the exact treatment of the quaternion process state-dependent noise and the quaternion measurement state-dependent noise under the framework of continuous-time optimal linear filtering. This yields statistically consistent covariance computations within the proposed filter without requiring tuning. The case of white noises in the gyro and vector measurements are considered in this work. This paper also presents the development of a Sun vector determination subsystem for the nanosatelite Delfi-N3xt. Simulations and preliminary experimental validation show that this subsystem, which consists of six four-quadrant Sun sensors, can deliver a Sun-spacecraft line of sight with an averaged equivalent angular error of approximately 0.2 deg without the Earth albedo. The performances of the novel filter are illustrated via extensive Monte-Carlo simulations in the case of Delfi-N3xt, where Sun vector measurements, Earth magnetic measurements and gyro measurements are acquired along a 600 km height Sun synchronous orbit. The proposed filter appears to be insensitive to poor initial conditions and low sampling rates. It converges where a standard extended Kalman filter fails to do so under the same conditions.Space EngineeringAerospace Engineerin

Therapeutic Advances and Future Prospects in Immune-Mediated Inflammatory Myopathies

The inflammatory myopathies include three distinct entities: polymyositis (PM), dermatomyositis (DM), and inclusion body myositis (IBM). A T-cell-mediated cytotoxic process in PM and IBM and a complement-mediated microangiopathy in DM are the hallmarks of the underlying autoimmune processes. The most consistent therapeutic problem remains the distinction of PM from the difficult-to-treat mimics such as s-IBM, necrotizing myopathies and inflammatory dystrophies. This review provides a step-by-step approach to the treatment of inflammatory myopathies, highlights the common pitfalls and mistakes in therapy, and identifies the emerging new therapies. In uncontrolled studies, PM and DM respond to prednisone to some degree and for some period of time, while a combination with one immu-nosuppressive drug (azathioprine, cyclosporine, mycophenolate, methotrexate) offers additional benefit or steroid-sparing effect. In contrast, IBM is resistant to most of these therapies, most of the time. Controlled studies have shown that IVIg is effective and safe for the treatment of DM, where is used as a second, and at times first, line therapy. IVIg seems to be also effective in the majority of patients with PM based on uncontrolled series, but it offers transient help to a small number of patients with IBM especially those with dysphagia. Bona fide patients with PM and DM who become resistant to the aforementioned therapies, may respond to rituximab, tacrolimus or rarely to an tumor necrosis factor alpha inhibitor. For IBM patients, experience with alemtuzumab, a T-cell-depleting monoclonal antibody, is encouraging